Objective: To examine the cost-effectiveness of therapeutic strategies for patients with toxic thyroid adenoma. Design: A decision analytic model was used to examine strategies, including thyroid lobectomy after a 3-month course of antithyroid drugs (ATDs), radioactive iodine (RAI), and lifelong ATDs followed by either RAI (ATD-RAI) or surgery (ATD-surgery) in patients suffering severe drug reactions. Methods: Outcomes were measured in quality-adjusted life years. Data on the prevalence of co-incident thyroid cancer, complications and treatment efficacies were derived from a systematic review of the literature (1966 -2000). Costs were examined from the health care system perspective. Costs and effectiveness were examined at their present values. Discounting (3% per year), variations of major cost components, and every variable for which disagreements exist among studies or expert opinion were examined by sensitivity analyses. Results: For a 40-year-old woman, surgery was both the most effective and the least costly strategy (e1391),while ATD-RAI cost the most (e5760). RAI was more effective than surgery if surgical mortality exceeded 0.6% (base-case 0.001%). RAI become less costly for women of more than 72 years (more than 66 in discounted analyses). For women of 85, ATD-RAI may be more effective than RAI and have an inexpensive marginal cost-effectiveness ratio (e4975) if lifelong follow-up results in no decrement in quality of life. Conclusions: Age, surgical mortality, therapeutic costs and patient preference must all be considered in choosing an appropriate therapy.
Introduction
Toxic thyroid adenoma causes thyrotoxicosis in European populations, particularly in cases of iodine deficiency (1 -6) . In European countries, patients with thyroid toxic adenoma represent 7 -11% of thyrotoxic patients (7) . Treatment options are surgery and radioactive iodine (RAI) (5, (8) (9) (10) . The most common surgical procedure is unilateral thyroid lobectomy (11 -15) . Advocates for surgery claim that surgery rapidly controls the thyrotoxicosis and lowers the risk of missing incidental thyroid cancers associated with the adenoma, while having negligible mortality and morbidity. Advocates for RAI note that it is effective and carries no immediate risk of mortality. In addition, hypothyroidism resulting from RAI is rare and relapse of the toxic adenoma is uncommon. Furthermore, long-term carcinogenic risk or genetic injury resulting from RAI remain, at this time, only theoretical concerns. Finally, some authors consider RAI to be the least expensive treatment for hyperthyroidism and encourage its greater use (16) . Longterm therapy with antithyroid drugs (ATDs) is seldom used because, while surgery and RAI will cure the patient, ATDs will never do so due to the intrinsic nature of the adenoma (neoplasm generally due to a somatic mutation of the thyrotropin (TSH) receptor). Moreover, withdrawal of ATD therapy will generally end up in relapse. While intra-lesional injection of ethanol has also been proposed (10) , this treatment remains experimental (17) . Although surgery and RAI are time-honored treatments, they have never been compared in a randomized trial; choice of therapy has typically depended upon locally available facilities and expertise. Our objective was to compare the costs and the outcomes (survival and quality of life) of therapeutic strategies for thyroid adenoma.
Methods

Case definition
A toxic solitary thyroid nodule was defined as one which demonstrated uptake with suppressed uptake in the surrounding thyroid tissue in a thyroid scintiscan in an individual with clinical hyperthyroidism (9, 18, 19) . Patients with non-toxic autonomously functioning nodules were not considered. Since toxic thyroid adenomas are most common in women between 30 and 50 years of age (17, 19 -21) we considered the base-case of a 40-year-old woman. We have assumed that all toxic thyroid adenomas must be treated.
Description of decision analytic model
We examined the cost-effectiveness of four mutually exclusive strategies. (A) Primary RAI. (B) Primary surgery -thyroid lobectomy once euthyroidism has been achieved with ATDs. (C) Lifelong medical therapy with ATDs followed by either surgery (ATD-surgery) or (D) RAI (ATD-RAI) in the event of a serious drug reaction. We used Decision Maker (22, 23) , a decision analysis software program to model these strategies as a recursive decision model (24) with a lifetime horizon. (The decision tree is available on request from G M Vidal-Trécan.)
Effectiveness
Outcomes were expressed both as overall life expectancy (LE) and as quality-adjusted life expectancy (QALE), using a declining exponential approximation of the 'DEALE' (25) . Population-based mortality rates were derived from tables of vital statistics. Mortality rates for patients with co-incident thyroid cancer (Table 1) detected during surgical procedure and treated have been estimated to be 0.002 per year (5-year survival: 99%) for patients under the age of 50 years and 0.023 per year (5-year survival: 89%) for patients 50 years of age or older (26) . Primarily undetected thyroid cancer might progress in all non-surgical strategies and increase mortality. Excess mortality from those cancers was estimated from treated patients who developed locally extensive or metastatic thyroid cancer (27, 28) . Long-term complications of RAI included recurrent hyperthyroidism, permanent hypothyroidism, and radiation-induced thyroid cancer. The prognosis of radiation-induced thyroid cancer was modeled as being equivalent to undetected thyroid cancer. Short-term complications of surgery included hematoma and transient vocal cord paralysis, transient hypothyroidism, and anesthesia-related death. Major complications of ATD therapy including agranulocytosis, hepatitis and vasculitis (9, 29, 30) occurred at both 7 weeks and 6 months after the start of therapy. They resulted in hospitalization, the discontinuation of ATDs, or death. Patients who survived underwent either lobectomy or treatment with RAI. Some minor adverse effects such as rash, urticaria and arthralgias (8) possibly led to discontinuation of ATDs.
Quality of life
We adjusted LE for both acute and chronic morbidities. These quality-adjustment factors were mostly based on published data supplemented by expert judgment (Table 1) (31) . QALE for chronic morbidities were modeled as quality of life coefficients multiplied by the total LE while acute morbidities were subtracted from LE. Continued monitoring for euthyroidism, hypothyroidism and permanent dysphonia resulted in decreased quality of life (31) .
Resource use
The costs for each strategy were estimated for two periods: (A) the initial year following diagnosis and (B) the subsequent remaining years of life (Table 2) .
Surgical treatment Patients received a 3-month course of ATDs prior to surgery (14, 20, 32) . Hematoma resulted in a longer hospitalization and an associated decrement in quality of life. Transient vocal cord palsies required vocal cord re-education; permanent hypothyroidism required long-term treatment and follow-up. In the base-case we assumed lobectomy to be 100% effective and patients were followed for only 1 year. If a thyroid cancer was detected, a total thyroidectomy was performed and 3700 MBq RAI was prescribed. Patients required lifelong surveillance for treatment with TSH-suppressive levothyroxine and recurrent thyroid cancer or metastases that were not modeled. The cost components of thyroid cancer treatment were drawn from expert opinion. Guidelines for treatment of patients with hyper-and hypothyroidism (Agence Nationale d'Accreditation et d'Evaluation en Santé) were used to establish the periodicity of clinical visits and laboratory tests.
Medical treatments Patients initially treated with RAI were pretreated with b-blockers, received outpatient RAI and required lifetime follow-up. Transient hyperthyroidism following RAI required a course of ATDs.
Failure to control hyperthyroidism resulted in the administration of up to three courses of RAI. Patients with hyperthyroidism after three courses of RAI underwent surgery. In the base-case, a high dose of RAI was used (i.e. 555 -1850 MBq (15 -50 mCi)) because it is considered more effective than low-dose therapy (11, 20, 33 -39) .
The follow-up of lifelong therapy with ATDs required four ambulatory visits during the first year, and two in subsequent years. (11, 33, 34, (36) (37) (38) 0.185 0.064 -0.306 0.99 Recurrent hyperthyroidism (11, 31, (33) (34) (35) (36) 38) 0.014 0 -0.045 95 Radio-induced thyroid cancer (31, 43, 61, 63) 0.000 (0-0.008) § 0.83 Surgery Dysphonia (12, 15, 32, 50) 0.030 0.015 -0.040 0.98 Hypothyroidism (11-15, 32, 39) 0.040 0.020 -0.054 0.99 * Quality-adjustment factors reflect the relative desirability of each health state or event. They usually result from expert judgment, values from the literature or values from measurements on a sample of subjects (40) . † For short-term outcomes, quality-adjustment factor is expressed in days and subtracted from life expectancy. ‡ For long-term outcomes, quality-adjustment factor is multiplied by life expectancy. § Range of rates examined in the sensitivity analyses. NA, not applicable. 
Costs
Costs were estimated from the perspective of the health care system and are expressed in 2001 Euros. Average total inpatient costs were derived from the cost accounting system of the Assistance Publique-Hôpitaux de Paris (AP-HP). The AP-HP is a hospital network of 50 non-profit university hospitals in the Paris region. Non-healthcare costs such as losses in productivity or costs outside the health system (e.g. family time) were not considered. Hospital costs included all personnel costs, supplies, drugs and blood products, tests, housekeeping and hospital overheads. Ambulatory costs were estimated using the national reimbursement schedule provided by the Social Security, prices for drugs were derived from the French Red Book (Dictionnaire Vidal). Costs and health benefits in the remaining years of life were examined at their present value (40) . The cost of treating localized thyroid cancer discovered at surgery was the sum of the costs of a hospitalization for total thyroidectomy, an evaluation for thyroid cancer, and one course of ablative radioiodine therapy (e4939) and ambulatory visits each year to confirm the absence of progression of disease (e158). Information provided by Eeckhoudt et al. (41) was used to estimate the cost of a primarily undetected thyroid cancer. For the first year this was estimated as the costs from one surgical hospitalization and from one hospitalization for the administration of 3700 MBq RAI (e5028). Lifetime costs included those of one surgical hospitalization for recurrent thyroid cancer, ambulatory visits to evaluate the progression of disease each year, and four hospitalizations each for the administration of 3700 MBq RAI (on average e561 each year). In both cases, the lifetime cost for hypothyroidism was included. In sensitivity analyses, the cost of permanent hypoparathyroidism was estimated to be e353 for the first year and e309 for subsequent years including the cost of therapy and follow-up.
Cost-effectiveness analysis
Incremental cost-effectiveness ratios were computed using the costs and the outcomes of both strategies.
Data used in the model
We reviewed both the English and the French language medical literature from 1966 to 2000 using a structured Medline search supplemented by manual searches of bibliographies of selected articles. Studies were excluded if they did not report separate results for both autonomously functioning adenomas, and/or toxic nodular goiters. If the same patient series was published in more than one journal, only data from the latest publication were included. Mean estimates for each variable in the model were used for the base-case analysis ( Table 1) .
Prevalence of thyroid cancer in association with toxic adenoma Thyroid carcinoma was associated with toxic adenoma in 0.7% of patients undergoing thyroidectomy (95% confidence intervals (CI): 0.3 -1.2%) across studies (11 -15, 20, 32, 33, 35, 39, 42 -49) . The toxic thyroid nodule itself seldom contained the cancer. Co-incident thyroid cancers found at surgery were mostly intrathyroidal and of the microcancer type.
Complications from surgery Local complications from lobectomy (11 -15, 32, 39, 50) included transient vocal cord palsies (5.8%; extreme values: 0.0 -8.3%) and hematoma (2.0%; 95% CI: 1.0 -3.0%). Transient hypothyroidism (4.2%, 95% CI: 1.4 -7.1%) was usually mild and early recovery was common.
Potential long-term complications from lobectomy included persistent dysphonia (2.8%; 95% CI: 1.5 -4.0%) and permanent hypothyroidism (3.7%; 95% CI: 2.0 -5.4%). Anesthesia-related death ranged from 1/13 207 to 1/185 000 (51) . No surgical deaths were reported when patients were pretreated with ATDs.
Recurrence never happened after total lobectomy. In the sensitivity analyses, the risk of complications was assumed to be same as for the primary lobectomy except for the risk of hypoparathyroidism which was estimated to be respectively 6% for transient and 0.6% for permanent hypoparathyroidism (52) .
RAI dosing and complications Results were stratified into those of high-dose RAI (555 -1850 MBq or 15 -50 mCi) and low-dose RAI (40 -554 MBq or 1 mCi-, 15 mCi) therapy. The first dose failure rate for high doses was 7.8% (95% CI: 0.0 -15.7%), for low-doses it was 14.1% (95% CI: 8.7 -19.5%) (11, 13, 14, 33, 35, 36, 39, 53 -58) . We used expert opinion to estimate the risk of transient mild hyperthyroidism due to RAI and assumed that this could not be more frequent than failure to control hyperthyroidism. In most published studies, the incidence of hypothyroidism increased over time after treatment with RAI. In a subset of studies where patients with high-dose therapy were followed beyond 10 years (11, 33 -38 ) the average rate of hypothyroidism was 18.5% (95% CI: 6.4 -30.6%) while the average rate of recurrent hyperthyroidism was 1.4% (95% CI: 0.0-4.5%). In follow-up studies of patients receiving low-dose therapy (14, 36, 53 -55, 59 ) these figures were 5.6% (95% CI: 1.8 -9.4%) and 5.4% (95% CI: 1.6 -9.1%) respectively. Three of seven published studies evaluating thyroid cancer risk following RAI treatment for benign lesions (43, 60 -65) demonstrated an increased relative risk (60, 64, 65) . Considering the average latency period for thyroid cancer induced by external radiation (12 years or longer) (66 -68), we modeled occurrence of thyroid cancer 12 years after RAI administration. However, the data in Franklyn et al. (65) indicate that thyroid cancer could be diagnosed 7.5 years after RAI therapy. In the base-case analysis, we assumed no increased risk of thyroid cancer in patients receiving RAI. RAI exposure after the 10th week of gestation may cause fetal hypothyroidism and may be an indication for therapeutic abortion (16, 69) .
Adverse reactions of ATD therapy In patients treated with methimazole, 0.3% developed agranulocytosis (70) . The risks of drug-induced hepatitis, vasculitis and other adverse effects leading to discontinuation of ATDs were estimated at 1% (8) . In our base-case analysis, we used a mortality rate from major complications of ATDs of 0.1% (71) . Rarely, infant defects may be associated with the use of methimazole in pregnancy (9) , leading to the use of propylthiouracil in this circumstance. This was assumed not to change the rates of adverse effects and the medication costs.
Other medical therapy
Studies of patients receiving lifelong replacement levothyroxine therapy (72, 73) after thyroid ablative therapy did not show increased mortality except in the cases when doses were higher than those used for substitution therapy.
Sensitivity analyses
Sensitivity analyses were performed on every variable for which disagreements among studies or expert opinions had been found in the literature. The extreme values of reported data or the estimated 95% CI were used (Table 1 ). In addition, we also tested the effects of variations in value of major cost components (i.e. length of hospitalization, frequency of ambulatory follow-up).
Recurrence of toxic thyroid adenoma was considered after a delay and resulted in a course of ATDs and contralateral lobectomy. These treatments may result in the same short-term or long-term complications as the previous surgical procedure; the risk of transient or permanent hypoparathyroidism should be added to these risks.
Both costs and effectiveness discounted at 3% per year to account for time preference and inflation (74) were examined. Most authors consider that if costs are discounted then medical outcomes such as life years gained must also be discounted (75) . Treatment with RAI is an absolute contraindication to pregnancy and lactation during the year following RAI administration. The reduction in quality of life for women of childbearing age was only considered in sensitivity analyses of short-term morbidity.
Results
Base-case analysis
In the base-case of a 40-year-old woman (Table 3A) , with toxic thyroid adenoma, primary thyroid lobectomy after a 3-month course of ATDs was the least expensive and the most effective strategy, resulting in a gain of 0.24 QALYs, as compared with RAI. ATD-surgery or ATD-RAI cost more and were less effective than surgery and RAI.
Sensitivity analyses
All sensitivity analyses were performed using present values for both costs and effectiveness unless otherwise noted.
Patient age
We examined the effect of age in otherwise healthy women between 15 and 85 years (Table  4) . Surgical mortality related to anesthesia was adjusted accordingly, from 0.001% in patients less than 60 years of age, to 0.002% between the ages of 60 and 80, and to 0.003% over the age of 80. Surgery was the most effective strategy for women of all ages studied. Only for women of more than 72 did RAI become less costly.
Mortality from surgery RAI was more effective than surgery when the surgical mortality risk exceeded Table 3 Base-case analysis (40-year-old woman) of (A) cost and effectiveness of management strategies and (B) discounted cost and effectiveness strategies for thyroid toxic adenoma*. † QALE denotes quality-adjusted life expectancy (effectiveness) expressed in QALYs in (A) and discounted at 3% per year in (B). ‡ QALYs are quality-adjusted life years. { DS denotes dominated strategy, i.e. the strategy in this row is both less effective and more costly than the one in the row above.
0.6%. This threshold decreased slightly with age from 0.7% for a 15-year-old woman to 0.5% for an 85-year-old woman. When the risk of death exceeded 0.7%, the marginal cost-effectiveness of RAI versus surgery was relatively inexpensive from 40 and decreased with age until 72 years old and with increment of risk of death from surgery ( Fig. 1 ).
Efficacy and other complications of surgery Surgery remained the most effective strategy unless the risk of permanent hypothyroidism exceeded 61% and the risk of permanent dysphonia exceeded 31% and the least costly unless the risk of permanent hypothyroidism exceeded 49%. All these thresholds decreased slightly with age (Table 5 ) but never reached levels contained in the estimated 95% CI or published extreme values.
RAI dosing, efficacy and complications The efficacy and complication rates of RAI were different for high-and low-dose treatments. Low-dose RAI resulted in 0.05 more quality-adjusted life years (QALYs) than high-dose therapy in our base-case with an estimated average lifetime cost of e2644. Thus low-dose RAI dominated high-dose RAI.
Lowering the risk of RAI complications did not make this strategy less costly than surgery. When the risk of developing a radio-induced thyroid cancer was considered, the cost of RAI increased and its effectiveness decreased.
Prevalence of a co-incident thyroid cancer The prevalence of thyroid cancer varied from 0.3% to 1.2% in sensitivity analyses. Throughout this range, surgery was preferred, resulting in a gain of 0.15 QALYs for a prevalence of 0.3%, and 0.35 QALYs for a prevalence of 1.2%. The difference in costs of surgery versus RAI administration increased from e1369 to e1518.
Quality of life adjustment factors Quality of life adjustment factors for most morbidities were derived from expert opinion. The model was relatively insensitive to these factors. Sensitivity analyses over reasonable ranges for these variables did not change the outcomes of the strategies significantly whatever the age of the patients (Table 5) .
For our base-case, lobectomy should result in a loss of 0.31 QALYs (113 days) to be less effective than RAI. For women of 85, if lifelong surveillance and therapy result in no decrement in quality of life, then ATD-RAI is more effective than RAI administration and has a marginal cost-effectiveness ratio of e4975 compared with RAI.
If we perform our analysis using quality-unadjusted outcomes then surgery provides a gain of 0.16 years over RAI. Surgery remained the most effective strategy unless surgical risk exceeded 0.4%, at which point RAI became more effective.
Costs In undiscounted analyses, the only situations where surgery is more expensive than RAI are those in Table 4 Cost-effectiveness of competing strategies for management of thyroid toxic adenoma by age group*.
Strategy
Cost (e) which the cost of lobectomy exceeds e2596 (187% more than the base-case) or if the cost of the life-long ambulatory follow-up after RAI administration is less than e0.16. These differences varied with age and were possible for a 70-year-old woman (Table 5) . The model is insensitive to variations in costs of thyroid cancer treatment and follow-up. In discounted analyses, the costs of RAI administration and of the medical strategies (Table 3B) were lower than in nondiscounted analyses because of the longer term effects of RAI. Above 66 years of age RAI became the least costly.
Discussion
The choice between RAI and lobectomy for toxic thyroid adenoma has until now largely depended on expert opinion. This is because outcomes in thyroid diseases have seldom been evaluated using randomized clinical trials and, to our knowledge, only three (26, 76, 77) decision analyses for thyroid diseases have been published, none of which examined toxic thyroid adenoma. Our analysis comparing thyroid lobectomy with 555 MBq RAI and the unusual lifelong therapy with ATDs showed that for an otherwise healthy 40-year-old woman lobectomy is the preferred strategy. This result is explained by the high effectiveness and low anesthesia-related risk of surgery compared with alternative strategies (11 -15, 20, 32, 33, 35, 39, 42 -49, 51 ). This result is robust for rates of anesthesia-related mortality under 0.5%. Another element of the high effectiveness of surgery is the prevalence of co-incident thyroid cancers, which are definitively removed. We estimated, from surgical series, that the prevalence of co-incident thyroid cancers is 0.7% (95% CI: 0.3 -1.2%) (11 -15, 20, 32, 33, 35, 39, 42 -49) ; we assumed that missing thyroid cancer during surgery was unlikely which may have biased our analysis slightly in favor of surgery. The other strategies were assumed to occasionally miss thyroid cancer, delaying diagnosis and resulting in a small risk of disseminated disease and a higher risk of death and higher costs. Differences in the unadjusted longterm health outcomes between all the strategies were smaller than the quality-adjusted health outcomes. The modest decrement in quality of life associated with the lifelong clinical follow-up that is required with either ATDs or RAI strategies explained their lower QALE when compared with lobectomy.
In the base-case, surgery was less costly than RAI administration. The differences were explained mostly by higher lifetime follow-up costs rendered necessary by the delayed risk of hypothyroidism after RAI administration, even if the annual costs of follow-up and hypothyroidism treatment are low (11 -14, 32, 35, 44, 78) . The lower costs of follow-up for surveillance or management of hypothyroidism offset the higher cost of surgery. Finally, the high lifetime costs of follow-up and therapy also explained the higher cost of the medical strategies. The average lifetime cost in the least expensive ATD strategy (i.e. ATD-surgery) exceeded the cost of RAI by e2915 in our base-case.
Our results also showed that the patient's age is an important consideration when choosing treatment.
Surgery is the less costly strategy for patients under the age of 72 years and of 66 years in discounted analyses, but RAI was preferred when the risk of surgical mortality exceeded 0.6% which is not unlikely in patients with multiple co-morbidities. For women of 85 years of age, lifelong treatment with ATDs (followed by RAI in case of an adverse reaction) was preferred to RAI.
We also assumed in our analysis that women would avoid pregnancy during the year following RAI administration, and that they would receive propylthiouracil as the ATD of choice. However, compliance may be poor. Since radiation exposure after the 10th week of gestation may cause fetal hypothyroidism, leading to therapeutic abortion (16) , lobectomy may be favored even more strongly in women under 50 years of age.
Our model was relatively insensitive to variations in procedural and follow-up costs for our typical patient. Surgery would become more expensive than RAI administration only if the cost of lobectomy were 187% over our base-case cost estimation and if the cost of ambulatory follow-up after RAI were very low.
Estimating the probability of post-radiation morbidity from small series was difficult (11, 14, 20, 33 -39, 53 -56, 58, 59, 79) The frequency of permanent hypothyroidism due to RAI increased over time. Both the efficacy and the prevalence of post-RAI hypothyroidism varied with the size of the radiation dose. Low-dose RAI was both less expensive and slightly more effective than high-dose RAI. It provided 18 days more of QALE than high-dose therapy due to the lower frequency of hypothyroidism. The risk of radiation-induced cancer in patients treated with RAI for benign thyroid diseases remains controversial. In our base-case analysis we assumed there was no risk of radiation-induced thyroid cancer. Three reports (60, 64, 65) have found an increased relative risk while others (43, 61, 63) have not. Furthermore, some of them (60, 63) have noted a small increased risk of other cancers. We explored this in sensitivity analyses. If the probability of developing a radioinduced thyroid cancer were considered, the differences in effectiveness and in cost of RAI with surgery would slightly increase.
Our study has some limitations. Risk aversion for surgery was not considered. As thyroid toxic adenoma cannot be considered as a chronic disease, we designed a simple recursive tree to model outcomes and costs of its management. However, therapeutic choices may result in long-term consequences, such as radio-induced hypothyroidism or thyroid cancer. Therefore, using a Markov model may have provided more precise results (80) . However, we did not find data describing the time-dependent function for radio-induced hypothyroidism specifically in patients with toxic thyroid adenoma and thyroid radiation-induced cancer. Quality of life following therapy is an important concern, especially in a disease with an otherwise good prognosis. Therefore, patient preferences must be factored into decision making. However, most complications are benign and reasonable changes in quality of life adjustment factors did not affect the results markedly.
Conclusion
Surgery is the most effective strategy across all ages unless patients have significant co-morbidities that would increase surgical mortality. It is also the least expensive strategy until 72 years of age (or 66 years of age in discounted analyses) across a wide range of assumptions. Thus it could be preferred to RAI for women up to 65 years old. For the eldest of patients, RAI is almost as effective as surgery and the least expensive strategy.
